Subtopic Deep Dive
Ginkgo biloba in Dementia Clinical Trials
Research Guide
What is Ginkgo biloba in Dementia Clinical Trials?
Ginkgo biloba in dementia clinical trials evaluates randomized controlled trials of standardized EGb 761 extracts for managing Alzheimer's disease and vascular dementia symptoms through cognitive outcomes, safety, and dose-response assessments.
Key trials like Le Bars (1997) tested EGb 761 in a placebo-controlled, double-blind study showing cognitive improvements in dementia patients. Meta-analyses such as Weinmann et al. (2010) reviewed multiple RCTs for effects on Alzheimer's and mixed dementia. Over 10 major papers from 1997-2010 provide evidence, with Le Bars cited 962 times.
Why It Matters
Standardized Ginkgo extracts like EGb 761 offer potential non-pharmacological options for dementia symptom relief in aging populations, as demonstrated in Le Bars (1997) trial with 202 patients showing ADAS-Cog score improvements. Weinmann et al. (2010) meta-analysis of 9 trials (2,561 patients) found modest cognitive benefits without major safety issues, informing complementary medicine guidelines. Doody et al. (2001) evidence review contextualizes Ginkgo among antioxidants like vitamin E for delaying dementia progression, impacting clinical decisions for millions with AD.
Key Research Challenges
Heterogeneous Trial Designs
RCTs vary in EGb 761 dosing (120-240 mg/day) and dementia subtypes (AD vs. vascular), complicating meta-analyses (Weinmann et al., 2010). Le Bars (1997) used 120 mg/day over 52 weeks, but shorter trials yield inconsistent results. Standardization of extracts remains inconsistent across studies.
Modest Effect Sizes
Benefits on cognitive scales like ADAS-Cog are small and clinically debatable (Doody et al., 2001; Weinmann et al., 2010). Le Bars (1997) reported 1.4-point improvement, below minimal clinically important difference. Long-term efficacy beyond 6 months lacks robust data.
Safety in Comorbid Populations
Interactions with anticoagulants pose risks in vascular dementia patients, underexplored in trials (Shaito et al., 2020). Doody et al. (2001) notes need for more data on antioxidants' safety profiles. Gender-specific responses, as in Viña and Lloret (2010), require further trials.
Essential Papers
Practice parameter: Management of dementia (an evidence-based review) [RETIRED]
Rachelle S. Doody, J E Stevens, C. Beck et al. · 2001 · Neurology · 1.7K citations
Cholinesterase inhibitors benefit patients with AD (Standard), although the average benefit appears small; vitamin E likely delays the time to clinical worsening (Guideline); selegiline, other anti...
Reversals of Age-Related Declines in Neuronal Signal Transduction, Cognitive, and Motor Behavioral Deficits with Blueberry, Spinach, or Strawberry Dietary Supplementation
James A. Joseph, Barbara Shukitt‐Hale, Natalia A. Denisova et al. · 1999 · Journal of Neuroscience · 973 citations
Ample research indicates that age-related neuronal-behavioral decrements are the result of oxidative stress that may be ameliorated by antioxidants. Our previous study had shown that rats given die...
A Placebo-Controlled, Double-blind, Randomized Trial of an Extract of Ginkgo Biloba for Dementia
Pierre Le Bars · 1997 · JAMA · 962 citations
<h3>Context.</h3> —EGb 761 is a particular extract of Ginkgo biloba used in Europe to alleviate symptoms associated with numerous cognitive disorders. Its use in dementias is based on positive resu...
Why Women Have More Alzheimer's Disease Than Men: Gender and Mitochondrial Toxicity of Amyloid-β Peptide
José Viña, Ana Lloret · 2010 · Journal of Alzheimer s Disease · 460 citations
The main risk factors for developing Alzheimer's disease (AD) are age and gender. The incidence of the disease is higher in women than in men, and this cannot simply be attributed to the higher lon...
Amyloid-β-Induced Pathological Behaviors Are Suppressed by<i>Ginkgo biloba</i>Extract EGb 761 and Ginkgolides in Transgenic<i>Caenorhabditis elegans</i>
Yanjue Wu, Zhixin Wu, Peter Butko et al. · 2006 · Journal of Neuroscience · 408 citations
Amyloid-β (Aβ) toxicity has been postulated to initiate synaptic loss and subsequent neuronal degeneration seen in Alzheimer's disease (AD). We previously demonstrated that the standardized Ginkgo ...
Herbal Medicine for Cardiovascular Diseases: Efficacy, Mechanisms, and Safety
Abdullah Shaito, Duong Thi Bich Thuan, Hoa Thi Phu et al. · 2020 · Frontiers in Pharmacology · 394 citations
Cardiovascular diseases (CVDs) are a significant health burden with an ever-increasing prevalence. They remain the leading causes of morbidity and mortality worldwide. The use of medicinal herbs co...
Neuroprotective and Antioxidant Effect of Ginkgo biloba Extract Against AD and Other Neurological Disorders
Sandeep Kumar Singh, Saurabh Srivastav, Rudolph J. Castellani et al. · 2019 · Neurotherapeutics · 359 citations
Reading Guide
Foundational Papers
Start with Le Bars (1997) for the landmark EGb 761 RCT (962 citations, 52-week trial details); Doody et al. (2001, 1722 citations) for evidence-based dementia management context including antioxidants; Weinmann et al. (2010) meta-analysis for synthesized RCT effects.
Recent Advances
Singh et al. (2019) reviews neuroprotective mechanisms; Shaito et al. (2020) covers safety in cardiovascular comorbidities relevant to vascular dementia.
Core Methods
RCTs employ ADAS-Cog for cognition, CIBIC for global function, with EGb 761 standardization (24% flavone glycosides, 6% terpene lactones); meta-analyses use random-effects models for heterogeneity (Weinmann et al., 2010).
How PapersFlow Helps You Research Ginkgo biloba in Dementia Clinical Trials
Discover & Search
Research Agent uses searchPapers('Ginkgo biloba EGb 761 dementia RCT') to find Le Bars (1997), then citationGraph reveals 50+ citing papers like Weinmann et al. (2010), and findSimilarPapers expands to meta-analyses on herbal dementia interventions.
Analyze & Verify
Analysis Agent applies readPaperContent on Le Bars (1997) to extract ADAS-Cog data, verifyResponse with CoVe checks meta-analysis claims from Weinmann et al. (2010), and runPythonAnalysis performs GRADE grading on effect sizes across 9 trials with pandas for forest plots and statistical verification of heterogeneity (I² statistic).
Synthesize & Write
Synthesis Agent detects gaps like long-term safety via contradiction flagging between Doody et al. (2001) and recent reviews; Writing Agent uses latexEditText for trial comparison tables, latexSyncCitations for 10+ papers, and latexCompile for a systematic review manuscript with exportMermaid for dose-response flowcharts.
Use Cases
"Run meta-analysis on Ginkgo dementia trials effect sizes with Python."
Research Agent → searchPapers → Analysis Agent → runPythonAnalysis (pandas meta-analysis on ADAS-Cog from Le Bars 1997, Weinmann 2010) → outputs forest plot CSV and GRADE-scored summary statistics.
"Draft LaTeX review of EGb 761 RCTs for Alzheimer's."
Synthesis Agent → gap detection → Writing Agent → latexEditText (structure sections) → latexSyncCitations (Doody 2001, Le Bars 1997) → latexCompile → outputs compiled PDF with bibliography.
"Find code for Ginkgo extract simulations in neurodegeneration models."
Research Agent → paperExtractUrls (Wu et al. 2006 C. elegans) → Code Discovery → paperFindGithubRepo → githubRepoInspect → outputs Python scripts for Aβ toxicity models linked to EGb 761 simulations.
Automated Workflows
Deep Research workflow scans 50+ Ginkgo dementia papers via searchPapers → citationGraph → DeepScan (7-step: extract outcomes, GRADE, meta-verify) → structured report on EGb 761 efficacy. Theorizer generates hypotheses on dose-response from Le Bars (1997) and Weinmann (2010) via gap detection → CoVe verification. DeepScan applies to safety profiles, chaining readPaperContent → runPythonAnalysis for adverse event pooling.
Frequently Asked Questions
What is the definition of Ginkgo biloba in dementia clinical trials?
It evaluates RCTs of standardized EGb 761 extracts for Alzheimer's and vascular dementia symptom management, focusing on cognitive outcomes like ADAS-Cog, safety, and dosing (Le Bars, 1997).
What are key methods in these trials?
Double-blind, placebo-controlled RCTs use EGb 761 at 120-240 mg/day over 24-52 weeks, measuring ADAS-Cog and CIBIC scales (Le Bars, 1997; Weinmann et al., 2010).
What are key papers?
Le Bars (1997, 962 citations) showed cognitive benefits in 202 patients; Weinmann et al. (2010, 282 citations) meta-analyzed 9 RCTs; Doody et al. (2001, 1722 citations) reviewed in dementia guidelines.
What are open problems?
Long-term efficacy beyond 1 year, optimal dosing, and interactions in comorbid elderly patients remain unresolved (Doody et al., 2001; Weinmann et al., 2010).
Research Ginkgo biloba and Cashew Applications with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Ginkgo biloba in Dementia Clinical Trials with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers